ScinnoHub Pharmaceutical Co., Ltd.

1. Single and multiple dose escalation trials Primary objective: To evaluate the safety and tolerability of BT-114143 in healthy subjects by single intravenous administration and multiple dose escalation, and to determine the Phase II recommended dose (RP2D). Secondary objective: To evaluate the pharmacokinetic characteristics of BT-114143 in healthy subjects by single intravenous administration and multiple dose escalation. Exploratory objective: To explore the biological effects of BT-114143 in healthy subjects; to explore the dose-exposure-effect relationship of BT-114143 in healthy subjects. 2. Biological effect exploratory trial Primary objective: To compare the antifibrinolytic activity and coagulation indexes of BT-114143 and positive control drugs in healthy subjects after single intravenous administration, to establish the dose-exposure-effect relationship of the drug as early as possible, and to provide a basis for the design of later clinical studies. Secondary objective: To evaluate the pharmacokinetic characteristics of BT-114143 and positive control drugs in healthy subjects by intravenous administration.

The primary objective is to evaluate the safety and tolerability of BT-1053 monotherapy in patients with relapsed/refractory B-cell lymphoma, in order to determine the maximum tolerated dose (MTD) and the recommended dose (RP2D) for Phase II clinical studies. The secondary objective is to determine the pharmacokinetic parameters of BT-1053 in patients with relapsed/refractory B-cell lymphoma and to preliminarily evaluate the overall efficacy of BT-1053 in some relapsed/refractory B-cell non-Hodgkin's tumor subtypes.

Phase Ib study on the safety, efficacy and pharmacokinetics of BT-114143 injection in the treatment of abnormal uterine bleeding